We’re finally going to see behind the Mirati curtain
Mirati Therapeutics has been one of 2019’s most curious biotech stories. The small company’s stock price has roughly doubled since the start of the year, but not because of success in a clinical trial, a rumored buyout, or a lucrative deal with pharma. Rather, it’s because the world is increasingly convinced so-called undruggable targets might actually fall prey to drugs.
Mirati has a treatment targeting KRAS, a protein implicated in a host of cancers that has largely proved impervious to medicinal chemistry. We’ve never actually seen human data on this drug, but a similar medicine from Amgen showed unprecedented results in lung cancer (its effects on colon cancer were less impressive), and thus the bull theory for Mirati is that its therapy will meet or even exceed that bar.
Soon none of this will be theoretical. Yesterday, Mirati disclosed that it will at last present human data on Oct. 28. We don’t know how many patients have been treated, how long they’ve been followed, and, of course, whether the drug had any effect. But at least we have a date.
Mirati has a treatment targeting KRAS, a protein implicated in a host of cancers that has largely proved impervious to medicinal chemistry. We’ve never actually seen human data on this drug, but a similar medicine from Amgen showed unprecedented results in lung cancer (its effects on colon cancer were less impressive), and thus the bull theory for Mirati is that its therapy will meet or even exceed that bar.
Soon none of this will be theoretical. Yesterday, Mirati disclosed that it will at last present human data on Oct. 28. We don’t know how many patients have been treated, how long they’ve been followed, and, of course, whether the drug had any effect. But at least we have a date.
.png)
No hay comentarios:
Publicar un comentario